Covid-19 and Fungal Co-Infection: A Literature Review with Special Reference to India
Keywords:Covid-19, Fungal co-infection, Aspergillosis, Mucormycosis, Candidiasis
Covid-19 pandemic and fungal co-infections have overwhelmed the healthcare facilities of many countries, including India. Development of secondary bacterial and fungal infections are well-known complications of viral pneumonia. In this pandemic situation, tracking the recent developments and disease epidemiology is of utmost importance to develop a better strategy to combat the disease. In the present study, a literature review was carried out to understand the status of fungal co-infections in Covid-19 patients. The study observed a high incidence of aspergillosis and candidiasis fungal infections in several European and American countries. While, in India, there was a surge in mucormycosis cases among Covid-19 patients. The use of vaccines and strict adherence to medical guidelines seems to be the only strategy to defeat Covid-19 pandemic and secondary infections.
Coronavirus disease (COVID-19) pandemic. WHO. https://www.who.int/emergencies/diseases/novel-coronavirus-2019/technical-guidance/naming-the-coronavirus-disease-(covid-2019)-and-the-virus-that-causes-it. Accessed on May 25, 2021.
Coronavirus (COVID-19) dashboard. WHO. https://covid19.who.int. Accessed on May 25, 2021.
Wu Z, Googan JM. Characteristics of and important lessons from the coronavirus disease 2019 (COVID-19) outbreak in China: summary of a report of 72314 cases from the Chinese Center for Disease Control and Prevention. JAMA. 2020:3231239.
Duong D. What is important to know about the new COVID-19 variants? CMAJ. 2021;193:E141-2.
SARS-CoV-2 variant classifications and definitions. CDC. https://www.cdc.gov/coronavirus/2019-ncov/variants/variant-info.html. Accessed on May 25, 2021.
Lai C, Wang C, Hsueh P. Co-infections among patients with COVID-19: the need for combination therapy with non-anti-SARS-CoV-2 agents? Journal of Microbiology, Immunology and Infection. 2020;53:505-12.
Yang S, Hua M, Liu X, Du C, Pu L, Xiang P, Wang L, Liu J. Bacterial and fungal co-infections among COVID-19 patients in intensive care unit. Microbes and infection. 2021;23:104806.
Zheng Z, Chen R, Li Y, Liu X, He W, Xu Y, He G, Li Y, Luo Q, Zhong N. The clinical characteristics of secondary infections of lower respiratory tract in severe acute respiratory syndrome. Chinese Journal of Respiratory and Critical Care Medicine. 2003;2:270-4.
MacIntyre CR, Chughtai AA, Barnes M, Ridda I, Seale H, Toms R, Heywood A. The role of pneumonia and secondary bacterial infection in fatal and serious outcomes of pandemic influenza a (H1N1) pdm09. BMC Infectious Diseases. 2018;18:1-20.
Zhu X, Ge Y, Wu T, Zhao K, Chen Y, Wu B, Zhu F, Zhu B, Cui L. Co-infection with respiratory pathogens among COVID-2019 cases. Virus Research. 2020;285:198005.
Chen N, Zhou M, Dong X, Qu J, Gong F, Han Y. Epidemiological and clinical characteristics of 99 cases of 2019 novel coronavirus pneumonia in Wuhan, China: a descriptive study. Lancet. 2020;395:507-13.
Yang X, Yu Y, Xu J, Shu H, Liu H, Wu Y, Zhang L, Yu Z, Fang M, Yu T, Wang Y. Clinical course and outcomes of critically ill patients with SARS-CoV-2 pneumonia in Wuhan, China: a single-centered, retrospective, observational study. The Lancet Respiratory Medicine. 2020;8:475-81.
Al-Hatmi AMS, Mohsin J, Al-Huraizi A, Khamis F. COVID-19 associated invasive candidiasis. Journal of Infection. 2021;82:e45-6.
Salmanton-Garcia J, Sprute R, Stemler J, Bartoletti M, Dupont D, Valerio M, Garcia-Vidal C, Falces-Romero I, Machado M, de la Villa S, Schroeder M. COVID-19–associated pulmonary aspergillosis, March–August 2020. Emerging Infectious Diseases. 2021 Apr;27:1077.
Bartoletti M, Pascale R, Cricca M, Rinaldi M, Maccaro A, Bussini L, Fornaro G, Tonetti T, Pizzilli G, Francalanci E, Giuntoli L. Epidemiology of invasive pulmonary aspergillosis among intubated patients with COVID-19: a prospective study. Clinical Infectious Diseases. 2021;73:e3606-14.
Zhang G, Hu C, Luo L, Fang F, Chen Y, Li J, Peng Z, Pan H. Clinical features and short-term outcomes of 221 patients with COVID-19 in Wuhan, China. Journal of Clinical Virology. 2020;127:104364.
Bardi T, Pintado V, Gomez-Rojo M, Escudero-Sanchez R, Azzam Lopez A, Diez-Remesal Y, Martinez Castro N, Ruiz-Garbajosa P, Pestaña D. Nosocomial infections associated to COVID-19 in the intensive care unit: clinical characteristics and outcome. European Journal of Clinical Microbiology & Infectious Diseases. 2021;40:495-502.
Rabagliati R, Rodríguez N, Núñez C, Huete A, Bravo S, Garcia P. COVID-19–associated mold infection in critically Ill patients, Chile. Emerging Infectious Diseases. 2021;27:1454-6.
Mohamed A, Rogers TR, Talento AF. COVID-19 associated invasive pulmonary aspergillosis: diagnostic and therapeutic challenges. Journal of Fungi. 2020;6:115.
Prestel C, Anderson E, Forsberg K, Lyman M, de Perio MA, Kuhar D, Edwards K, Rivera M, Shugart A, Walters M, Dotson NQ. Candida auris outbreak in a COVID-19 specialty care unit—Florida, July–August 2020. Morbidity and Mortality Weekly Report. 2021 Jan 15;70(2):56-7.
White LP, Dhillon R, Cordey A. A national strategy to diagnose COVID-19 associated invasive fungal disease in the ICU. Clinical Infectious Diseases. 2020:1298.
Antinori S, Bonazzetti C, Gubertini G, Capetti A, Pagani C, Morena V, Rimoldi S, Galimberti L, Sarzi-Puttini P, Ridolfo AL. Tocilizumab for cytokine storm syndrome in COVID-19 pneumonia: an increased risk for candidemia?. Autoimmunity Reviews. 2020;19:102564.
Salehi M, Ahmadikia K, Mahmoudi S, Kalantari S, Jamalimoghadamsiahkali S, Izadi A, Kord M, Dehghan Manshadi SA, Seifi A, Ghiasvand F, Khajavirad N. Oropharyngeal candidiasis in hospitalised COVID?19 patients from Iran: species identification and antifungal susceptibility pattern. Mycoses. 2020;63:771-8.
Allaw F, Kara Zahreddine N, Ibrahim A, Tannous J, Taleb H, Bizri AR, Dbaibo J, Kanj SS. First Candida auris outbreak during a COVID-19 pandemic in a tertiary-care center in Lebanon. Pathogens. 2021;10:157.
Hibbett DS, Binder M, Bischoff JF, Blackwell M, Cannon PF, Eriksson OE, Huhndorf S, James T, Kirk PM, Lücking R, Lumbsch HT. A higher-level phylogenetic classification of the Fungi. Mycological Research. 2007;111:509-47.
Moorthy A, Gaikwad R, Krishna S, Hegde R, Tripathi KK, Kale PG, Rao PS, Haldipur D, Bonanthaya K. SARS-CoV-2, uncontrolled diabetes and corticosteroids-an unholy trinity in invasive fungal infections of the maxillofacial region? a retrospective, multi-centric analysis. Journal of Maxillofacial and Oral Surgery. 2021;20:418-25.
Khurana S, Singh P, Sharad N, Kiro VV, Rastogi N, Lathwal A, Malhotra R, Trikha A, Mathur P. Profile of co-infections & secondary infections in COVID-19 patients at a dedicated COVID-19 facility of a tertiary care Indian hospital: implication on antimicrobial resistance. Indian Journal of Medical Microbiology. 2021;39:147-53.
Nehara HR, Puri I, Singhal V, Sunil IH, Bishnoi BR, Sirohi P. Rhinocerebral mucormycosis in COVID-19 patient with diabetes a deadly trio: case series from the north-western part of India. Indian Journal of Medical Microbiology. 2021;39:380-3.
Vijay S, Bansal N, Rao BK, Veeraraghavan B, Rodrigues C, Wattal C, Goyal JP, Tadepalli K, Mathur P, Venkateswaran R, Venkatasubramanian R. Secondary infections in hospitalized COVID-19 patients: Indian experience. Infection and Drug Resistance. 2021;14:1893-903.
Singh AK, Singh R, Joshi SR, Misra A. Mucormycosis in COVID-19: a systematic review of cases reported worldwide and in India. Diabetes & Metabolic Syndrome: Clinical Research & Reviews. 2021;15:102146.
Sen S, Lahane S, Lahane TP, Parekh R, Honavar SG. Mucor in a viral land: a tale of two pathogens. Indian Journal of Ophthalmology. 2021;69:244-52.
Sarkar S, Gokhale T, Choudhury S, Deb AK. COVID-19 and orbital mucormycosis. Indian Journal of Ophthalmology. 2021;69:1002-4.
Chowdhary A, Tarai B, Singh A, Sharma A. Multidrug-resistant Candida auris infections in critically ill coronavirus disease patients, India. Emerging Infectious Diseases. 2020;26:2694-96.
Revannavar SM, Supriya PS, Samaga L, Vineeth VK. COVID-19 triggering mucormycosis in a susceptible patient: a new phenomenon in the developing world?. BMJ Case Reports CP. 2021;14:e241663.
Gangneux JP, Bougnoux ME, Dannaoui E, Cornet M, Zahar JR. Invasive fungal diseases during COVID-19: we should be prepared. Journal de Mycologie Medicale. 2020;30:100971.
Dagenais TR, Keller NP. Pathogenesis of Aspergillus fumigatus in invasive aspergillosis. Clinical Microbiology Reviews. 2009;22:447-65.
Kousha M, Tadi R, Soubani AO. Pulmonary aspergillosis: a clinical review. European Respiratory Review. 2011;20:156-74.
Iwen PC, Rupp ME, Langnas AN, Reed EC, Hinrichs SH. Invasive pulmonary aspergillosis due to Aspergillus terreus: 12-year experience and review of the literature. Reviews of Infectious Diseases. 1998;26:1092-7.
Azoulay E, Timsit JF, Tafflet M, de Lassence A, Darmon M, Zahar JR, Adrie C, Garrouste-Orgeas M, Cohen Y, Mourvillier B, Schlemmer B. Candida colonization of the respiratory tract and subsequent pseudomonas ventilator-associated pneumonia. Chest. 2006;129:110-7.
Mucormycosis. CDC. https://www.cdc.gov/fungal/diseases/mucormycosis/index.html. Accessed on May 29, 2021.
Mayer FL, Wilson D, Hube B. Candida albicans pathogenicity mechanisms. Virulence. 2013;4:119-28.
Ribes JA, Vanover-Sams CL, Baker DJ. Zygomycetes in human disease. Clinical Microbiology Reviews. 2000;13:236-301.
Variants and genomic surveillance for SARS-CoV-2. CDC. https://www.cdc.gov/coronavirus/2019-nCoV/index.html. Accessed on May 27, 2021.
Spellberg B, Edwards J, Ibrahim A. Novel perspectives on mucormycosis: pathophysiology, presentation, and management. Clinical Microbiology Reviews. 2005;18:556-69.
How to Cite
Copyright (c) 2022 Advanced Journal of Science and Engineering
This work is licensed under a Creative Commons Attribution 4.0 International License.
This work is licensed under a Creative Commons Attribution 4.0 International License (CC-BY 4.0).